Replies to post #3047 on Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[ash111]

cap is about $18m per tase site.a joke.CPXX vs KTOV (per analysts):

ktov actually beats her on every parameter.there is no competition between these companies, completely different drugs&market potential.Comparison just to show major parameters like sales prediction, market cap,market potential, balance sheet,Ownership..."

CPXX sales prediction: $750m(US+EU) vs KTOV $1B(US alone,Blockbaster potential per Rodman & Renshaw).

Phase 3 completed on both. Marketing approval expected for both Q2-Q3 2017.

Market cap: CPXX: $1.1B vs KTOV $18M.

Ownership: CPXX about 12% vs KTOV 48.6% (As of March 4, 2016)

Cash&Debt: CPXX $23M in Cash, $19M Debt vs KTOV $21M in Cash,Zero Debt.

[Oceanfreedom]

Agree with Ash. All I care about is current OS of 6 million or market cap of 18 million. Will cross the fully diluted bridge in the future of around 12 mil as one would be looking at around an extra 20 million in cash on hand, imo. So at current prices fully diluted should actually make prices look even cheaper because warrants convert at 3.78

[zj3001]

Should be close to 13.3m ADS. I'll have to pull my notes when I get home.